CTRI/2023/03/050333
Not yet recruiting
Phase 4
A comparative, multicenter, prospective, randomized study to evaluate efficacy, safety and prevention of relapse with Elovera AD emollient vs plain emollient in mild to moderate atopic dermatitis
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: L209- Atopic dermatitis, unspecified
- Sponsor
- Glenmark Pharmaceuticals Limited
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients from 3 months\-75 yrs. of age.
- •2\. Patients who suffer from mild to moderate AD (IGA score of 2\-3\)
- •3\. Patients willing to provide informed consent/parental consent/assent.
Exclusion Criteria
- •1\. Patients not deemed fit to be prescribed topical steroids
- •2\. Patients not deemed to be fit to be prescribed emollients
- •3\. Patients unwilling to give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A multicenter, prospective, comparative, randomized, independent rater-blind, superiority, pivotal clinical trial to compare the safety and efficacy of the Cognitive therapy software ‘SUPERBRAIN DEX’ for improving cognitive function with a control group for patients with mild cognitive impairmentMental and behavioural disordersKCT0009133Hanyang University Guri Hospital126
Completed
Phase 2
Clinical study on AP/VJT/SBO Ayurvedic Hair Oil in femalesHealth Condition 1: L658- Other specified nonscarring hair lossCTRI/2022/05/042393AYURVED PRATISTHA
Active, not recruiting
Phase 3
A clinical research to study the safety, efficacy and immunogenicity of test pertuzumab in metastatic breast cancer patients.Health Condition 1: C50-C50- Malignant neoplasms of breastCTRI/2023/05/052997Enzene Biosciences Limited
Completed
Phase 3
Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteCTRI/2022/03/041271Zydus Research Centre Cadila Healthcare Limited268
Completed
Phase 3
Safety and efficacy Assessment of Trastuzumab emtansine of Cadila Healthcare Ltd in comparison with Reference drug(Trastuzumab emtansine) for the treatment of metastatic breast cancerHealth Condition 1: null- HER2- positive, metastatic breast cancerCTRI/2018/07/014881Cadila Healthcare Ltd168